EGFR and lung cancer: Recent studies showed that NCTD could overcome doxorubincin resistance in breast cancer cells and Hepatocyte growth factor (HGF) induced resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) in lung cancer cells.